Experience with St John's Wort (Hypericum perforatum) in children under 12 years with symptoms of depression and psychovegetative disturbances.
The value of an extract of Hypericum perforatum (St John's wort) for children with mild to moderate depressive symptoms was investigated for the first time in a multi-centre post-marketing surveillance study. One hundred and one children under 12 years were treated for a minimum of 4 weeks with an extension to 6 weeks with parental consent and medical practitioner recommendation. the dosage used ranged from 300 to 1800 mg per day. Compliance, tolerability and efficacy were assessed every 2 weeks by physicians and parents. Based on the data available for analysis, the number of physicians rating effectiveness as 'good' or 'excellent' was 72% after 2 weeks, 97% after 4 weeks and 100% after 6 weeks. The ratings by parents were very similar. There was, however, an increasing amount of missing data at each assessment point with the final evaluation including only 76% of the initial sample. Tolerability was good and no adverse events were reported. The results of this study suggest that Hypericum is a potentially safe and effective treatment for children with symptoms of depression.
Hübner
W D
WD
Lichtwer Pharma AG, Wallenroder Strasse 8-10, D-13435 Berlin, Germany.
Kirste
T
T
D000928:Antidepressive Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003863:Depression / Q000517:prevention & control*; D005260:Female; D006801:Humans; D020902:Hypericum / Q000627:therapeutic use*; D007223:Infant; D008297:Male; D010349:Patient Compliance; D008517:Phytotherapy; D010946:Plants, Medicinal; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D000928:Antidepressive Agents